reports
- Jonathan Moreland
WHF WHITEHORSE FINANCE INC.
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
CUBE CUBESMART
CE CELANESE CORPORATION
AZO AUTOZONE INC.
ALG ALAMO GROUP INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
NB NIOCORP DEVELOPMENTS LTD
OXM OXFORD INDUSTRIES INC.
AP AMPCO-PITTSBURGH
WMG WARNER MUSIC GROUP CORP.
NKE NIKE INC. CLASS B
ELAN ELANCO ANIMAL HEALTH INC.
AMCR AMCOR PLC
ENR EDGEWELL PERSONAL CARE COMPANY
SELF SELF STORAGE GROUP
DHC INC.
COO DIVERSIFIED HEALTHCARE TRUST
RZLT THE COOPER COMPANIES INC.
AZYO REZOLUTE
IMNM INC.
ACVA AZIYO BIOLOGICS
BMEA IMMUNOME
PBBK ACV AUCTIONS INC.
OWL BIOMEA FUSION
IMMX INC.
NUVL PB BANKSHARES
MAIA INC.
LIN BLUE OWL CAPITAL INC
WEST IMMIX BIOPHARMA INC
SMRT NUVALENT INC
FISV MAIA BIOTECHNOLOGY INC
XELB LINDE PUBLIC LIMITED COMPANY
SI WESTROCK COFFEE COMPANY LLC
ASST SMARTRENT INC
GMRE FISERV
SEVN INC.
MPTI XCEL BRANDS INC.
SHOULDER INNOVATIONS INC
ASSET ENTITIES INC.
GLOBAL MEDICAL REIT INC.
SEVEN HILLS REALTY TRUST
M-TRON INDUSTRIES
INC.
- Jonathan Moreland
AAON AAON INC.
WHF WHITEHORSE FINANCE INC.
SPG SIMON PROPERTY GROUP INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
HNRG HALLADOR ENERGY CO.
GOGO GOGO INC.
CUBE CUBESMART
CLFD CLEARFIELD INC.
AZO AUTOZONE INC.
ASA ASA
NB NIOCORP DEVELOPMENTS LTD
QTA QUATERRA RESOURCES INC.
WVE WAVE LIFE SCIENCES
IGR CBRE CLARION GLOBAL REAL ESTAT
WMG WARNER MUSIC GROUP CORP.
NKE NIKE INC. CLASS B
DIS THE WALT DISNEY COMPANY
ULBI ULTRALIFE
ELAN ELANCO ANIMAL HEALTH INC.
KOD KODIAK SCIENCES
EML THE EASTERN COMPANY
MIDD THE MIDDLEBY CORPORATION
PHR PHREESIA
DHC DIVERSIFIED HEALTHCARE TRUST
ALT ALTIMMUNE INC
COO THE COOPER COMPANIES INC.
RZLT REZOLUTE
AZYO INC.
DLHC AZIYO BIOLOGICS
AMR DALEIGH HOLDINGS CORP
BMEA ALPHA METALLURGICAL RESOURCES INC
WRB BIOMEA FUSION
NUVL INC.
MAIA W.R. BERKLEY CORPORATION
KVUE NUVALENT INC
GTE MAIA BIOTECHNOLOGY INC
NBBK KENVUE INC
SI GRAN TIERRA ENERGY INC.
ASST NB BANCORP INC.
MPTI SHOULDER INNOVATIONS INC
ASSET ENTITIES INC.
M-TRON INDUSTRIES
INC.
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a C...
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will host a conference call and live webcast at 4:00 p.m. ET on Wednesday, January 7, 2026 to provide an update on 12-month overall survival (OS) from its ongoing Phase 2a clinical trial of atebimetinib + modified G...
- Jonathan Moreland
ITW ILLINOIS TOOL WORKS INC.
AAON AAON INC.
SPG SIMON PROPERTY GROUP INC.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HNRG HALLADOR ENERGY CO.
GOGO GOGO INC.
CUBE CUBESMART
CLFD CLEARFIELD INC.
CE CELANESE CORPORATION
APLE APPLE HOSPITALITY REIT INC
NB NIOCORP DEVELOPMENTS LTD
QTA QUATERRA RESOURCES INC.
OXM OXFORD INDUSTRIES INC.
WVE WAVE LIFE SCIENCES
IGR CBRE CLARION GLOBAL REAL ESTAT
WMG WARNER MUSIC GROUP CORP.
DIS THE WALT DISNEY COMPANY
NWPP NEW PEOPLES BANKSHARES INC.
ULBI ULTRALIFE
ELAN ELANCO ANIMAL HEALTH INC.
KOD KODIAK SCIENCES
EML THE EASTERN COMPANY
MIDD THE MIDDLEBY CORPORATION
DHC DIVERSIFIED HEALTHCARE TRUST
COO THE COOPER COMPANIES INC.
RZLT REZOLUTE
AZYO INC.
NOG AZIYO BIOLOGICS
DLHC NORTHERN OIL AND GAS
IMNM DALEIGH HOLDINGS CORP
AMR IMMUNOME
BMEA ALPHA METALLURGICAL RESOURCES INC
LUCY BIOMEA FUSION
KVUE INC.
NBBK INNOVATIVE EYEWEAR INC
SI KENVUE INC
ASST NB BANCORP INC.
SHOULDER INNOVATIONS INC
ASSET ENTITIES INC.
- Jonathan Moreland
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimeti...
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA – End-of-Phase 2 interactions with FDA complete; scientific advice received from EMA – – Company expects to dose first patient in global Phase 3 registrational trial, MAPKeeper 301, in mid-2026 – – Overall survival update for Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients planned in coming weeks – NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-...
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evalu...
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of AtlantaResults demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal of Clinical Investigation Insight WP1066 found to be safe and effective, warranting a Phase 2 trial HOUSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin”...
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it is expected to be added to the Nasdaq Biotechnology Index (“NBI”) (Nasdaq: NBI). Immuneering’s addition will become effective prior to market open on Monday, December 22, 2025. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classifie...
- Jonathan Moreland
GLP GLOBAL PARTNERS LP
CLFD CLEARFIELD INC.
CDXS CODEXIS
NB NIOCORP DEVELOPMENTS LTD
QTA QUATERRA RESOURCES INC.
WVE WAVE LIFE SCIENCES
DIS THE WALT DISNEY COMPANY
ELAN ELANCO ANIMAL HEALTH INC.
MIDD THE MIDDLEBY CORPORATION
AMCR AMCOR PLC
RZLT REZOLUTE
ZNTL INC.
BMEA ZENTALIS PHARMACEUTICALS
NRDY BIOMEA FUSION
KVUE INC.
PROP NERDY INC.
NEXT KENVUE INC
SPRU PRAIRIE OPERATING CO.
MXF NEXTSOURCE MATERIALS INC.
GF SPRUCE POWER HOLDING CORP
AFCG THE MEXICO FUND
SI INC.
SEVN THE NEW GERMANY FUND
INC.
AFC GAMMA
INC.
SHOULDER INNOVATIONS INC
SEVEN HILLS REALTY TRUST
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Procee...
Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 727,969 shares of common stock of the Company originally issued in February 2025 at an exercise pri...
Moleculin Announces Completion of Treatment for the 45 Patients in Piv...
Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 Continues to drive enrollment with increase to 78% now consentedBlinded response activity tracking within expected range Consented subjects now across seven countries supporting the expansion of the MIRACLE trial HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today provided an update on enrollment from its November report with an increase to 78% of the target number of subjects for the first planned...
- Wedbush Research
SRPT SAREPTA THERAPEUTICS INC.
KURA KURA ONCOLOGY INC.
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
AMZN AMAZON.COM INC.
ARVN ARVINAS HOLDING
LYFT LYFT
UBER UBER TECHNOLOGIES INC.
BEAM BEAM THERAPEUTICS
COGT COGENT BIOSCIENCES INC
DASH DOORDASH
IMNM IMMUNOME
SANA SANA BIOTECHNOLOGY
CGEM CULLINAN ONCOLOGY INC
TCRX TSCAN THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
PRME PRIME MEDICINE INC
CART MAPLEBEAR INC.
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Martin Fan
- Ritika Das
- Robert Driscoll
Moleculin Announces New Annamycin Collaboration in Brain Tumors
Moleculin Announces New Annamycin Collaboration in Brain Tumors Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of Annamycin HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it has entered into a research and material transfer agreement with CIC biomaGUNE, a non-...
Prime Medicine Announces The New England Journal of Medicine Publicati...
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 clinical data with PM359, the Company’s investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease (CGD) in the New England Journal of Medicine (NEJM). The ...
Moleculin to Participate in the Virtual Investor Closing Bell Series
Moleculin to Participate in the Virtual Investor Closing Bell Series Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2nd at 4:00 PM ET HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that of Moleculin will participate in the on Tuesday, December 2, 2025 at 4:00 PM ET. As part of the event, Mr. Klemp will provide a corporate overview an...
Moleculin Announces Reverse Stock Split
Moleculin Announces Reverse Stock Split HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-25 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on December 1, 2025, and the Company’s common stock will open for trading on The Nasdaq Capital Market on December 1, 2025 on a post-split basis, under the e...
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 11:15 a.m. ET in Coral Gables, FL. A live audio webcast of the fireside chat will be available under “Events & Present...
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Con...
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Piper Sandler 37th Annual Healthcare Conference in New York City. Participating will be Ben Zeskind, Co-founder and Chief Executive Officer, Igor Matushansky M.D., Chief Medical Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Off...
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase ...
Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented Completion of treatment for the first 45 patients on pace for Q1 2026 with initial unblinded data thereafter; blinded response activity tracking within expected range HOUSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today provided an enrollment update with 60% of the target number of subjects for the first planned interim unblinding of data having consented to its pivotal Phase 2B/3 “MIRACLE” study of Annamycin in combination with c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.